Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]
, 2014 Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core +1 more source
PLoS ONE, 2015 AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts +5 more
doaj +1 more source
Pharmacological Research, 2022 Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory pathways have yet to be effectively targeted in clinical treatments for such ...
Katherine Kopp +3 more
semanticscholar +1 more source
Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro [PDF]
, 2003 The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoactive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP), glucagon, and peptide histidine ...
Alleaume, Céline +4 more
core +1 more source
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists [PDF]
Endocrinology and Metabolism, 2021 Glucagon-like peptide-1 (GLP-1) receptor agonists are efficacious glucose-lowering medications with salient benefits for body weight and cardiovascular events. This class of medications is now recommended as the top priority for patients with established
Hun Jee Choe, Young Min Cho
doaj +1 more source
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022 Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them.
Rishav Adhikari +7 more
semanticscholar +1 more source
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source
Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation [PDF]
, 2016 The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion.
A Bond +52 more
core +5 more sources
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]
Annals of Pediatric Endocrinology & Metabolism, 2017 The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj +1 more source
Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]
, 2010 Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Clar, C. +4 more
core +5 more sources